The NPPA has fixed the retail price of 29 formulations under Drugs Price Control Order (DPCO), 2013 through a notification dated 25 January 2019.
The formulations are telmisartan+cilnidipine + chlorthalidone tablet, paracetamol + diclofenac podium table, hydrochloride + diclofenac potassium tablet, atorvastatin + clopidogrel capsule, rosuvastatin + clopidogrel capsule, rosuvastatin + clopidogrel capsule, diclofenac sodium + chlorzoxazone tablet (Diclotal M), telmisartan + amlodipine + hydrochlorothiazide tablet (Telmiwock - AMH), metformin Hcl + glimepiride tablet (Glitop - M1), metformin Hcl + glimepiride tablet (Glitop - M2), amoxycillin + potassium C lavulanate tablet, paracetamol + phenylephrine Hcl + caffeine + diphenhydramine Hcl tablet, voglibose + metformin Hcl tablet, metoprolol tartrate + ramipril tablet, rosuvastatin + clopidogrel + aspirin capsule, methylcobalamin + alpha lipoic acid + pyridoxine hydrochloride + folic acid + vitamin D3 tablet (Nervijen D3), atorvastatin + clopidogrel capsule, etc.
The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of scheduled formulations in Form - III of Schedule - II of the DPCO, 2013 through IPDMS.
Any manufacturer intending to discontinue production of said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form -IV of Schedule - II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
The manufacturers not complying with the ceiling price and notes specified shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
